News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,549 Results
Type
Article (752)
Company Profile (2)
Press Release (794)
Section
Business (490)
Career Advice (1)
Deals (63)
Drug Delivery (1)
Drug Development (825)
FDA (100)
Job Trends (140)
News (1032)
Policy (359)
Tag
Academia (26)
Alliances (176)
Alzheimer's disease (2)
Antibody-drug conjugate (ADC) (9)
Approvals (91)
Artificial intelligence (6)
Bankruptcy (1)
Best Places to Work (136)
BIOSECURE Act (1)
Biosimilars (1)
Biotechnology (2)
Brain cancer (1)
Breast cancer (7)
Cancer (49)
Cardiovascular disease (2)
Career advice (1)
CAR-T (1)
CDC (5)
Cell therapy (5)
Clinical research (303)
Collaboration (7)
Complete response letters (2)
COVID-19 (506)
C-suite (4)
Cystic fibrosis (1)
Data (10)
Denatured (3)
Diagnostics (46)
Drug discovery (2)
Drug pricing (2)
Duchenne muscular dystrophy (2)
Earnings (163)
Editorial (5)
Events (134)
Executive appointments (1)
FDA (107)
Funding (6)
Gene editing (2)
Gene therapy (5)
GLP-1 (18)
Government (193)
Guidances (2)
Healthcare (129)
Immunology and inflammation (3)
Immuno-oncology (2)
Infectious disease (510)
Influenza (2)
IPO (32)
IRA (2)
Job creations (11)
Job search strategy (1)
Layoffs (7)
Legal (48)
Lung cancer (18)
Manufacturing (6)
MASH (1)
Medical device (14)
Medtech (14)
Mergers & acquisitions (34)
Metabolic disorders (11)
Neuroscience (2)
NextGen: Class of 2025 (9)
Non-profit (8)
Obesity (9)
Opinion (4)
Pancreatic cancer (1)
Patents (6)
Patient recruitment (1)
People (125)
Phase I (153)
Phase II (179)
Phase III (193)
Pipeline (18)
Policy (15)
Postmarket research (2)
Preclinical (59)
Prostate cancer (1)
Psychedelics (2)
Radiopharmaceuticals (2)
Rare diseases (8)
Real estate (14)
Regulatory (185)
Research institute (39)
RSV (3)
Series A (1)
Series B (2)
Sickle cell disease (1)
Special edition (2)
Startups (10)
Tariffs (1)
The Weekly (10)
Vaccines (188)
Venture capital (1)
Weight loss (3)
Date
Last 7 days (2)
Last 30 days (13)
Last 365 days (133)
2025 (99)
2024 (167)
2023 (165)
2022 (293)
2021 (354)
2020 (342)
2019 (43)
2018 (29)
2017 (15)
2016 (14)
2015 (14)
2014 (3)
2013 (4)
2012 (7)
Location
Africa (14)
Asia (147)
Australia (7)
California (2)
Canada (4)
China (10)
Europe (666)
Florida (1)
Indiana (1)
Maryland (10)
Massachusetts (11)
New Jersey (7)
New York (13)
Northern California (1)
Ohio (1)
South America (5)
United States (47)
1,549 Results for "biontech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
BioNTech Cuts 90 Jobs Amid ‘Strategic Alignment’
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing operations in Gaithersburg, Maryland.
August 6, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition
BioNTech will get CureVac’s early-stage cancer assets, including its mRNA-based glioblastoma therapy currently in Phase I development. CureVac had previously sued BioNTech for copyright infringement related to mRNA vaccine technology.
June 12, 2025
·
3 min read
·
Tristan Manalac
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Earnings
BioNTech’s Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing
BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said during the company’s Q1 investor call.
May 5, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
August 28, 2025
·
19 min read
Lung cancer
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC
Truist Securities called pumitamig’s data on Monday “very reassuring,” given the consistency between its performance in Chinese and global patient populations.
September 9, 2025
·
2 min read
·
Tristan Manalac
Patents
Moderna Wins UK Patent Battle Against Pfizer and BioNTech
A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.
August 1, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
BioNTech Commits to Infectious Diseases Amid Questions Over Vaccine Demand
The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of around 20% but that pricing and Comirnaty’s market share will hold steady.
August 4, 2025
·
2 min read
·
Nick Paul Taylor
Press Releases
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
August 5, 2025
·
28 min read
Pipeline
BioNTech Strives to Become Commercial ‘Powerhouse’ While Maintaining Humility
Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she will oversee BioNTech’s transition from a COVID-19 vaccine maker to an “end-to-end organizational oncology powerhouse.”
January 16, 2025
·
4 min read
·
Annalee Armstrong
1 of 155
Next
